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OBJECTIVE: To estimate aggregate burden imposed on the 
Australian community each year by the systemic rheumatic dis-
order ankylosing spondylitis (AS). METHODS: The study used
a bottom-up approach consisting of: a survey of 143 AS patients;
estimation of the costs associated with each patient; estimation
of the incidence and prevalence of AS in Australia; and integra-
tion of these data to estimate the total costs of AS in Australia
each year. The patient survey collected information about
respondents’ disease characteristics, quality of life, health care
resource utilisation, and employment. Health Care costs accrued
by patients were classiﬁed into six categories: medications; 
hospitalisations; specialist attendances; visits to other medical
professionals and allied health care appointments; medical pro-
cedures and tests; and complementary Health Care appoint-
ments. Non-Health Care costs comprised lost productivity due
to absence from paid and unpaid employment, assessed using the
human capital and friction cost methods, and using the value of
a quality-adjusted life year (QALY). RESULTS: It is estimated
the number of patients in the Australian health care system with
diagnosed AS is currently 6895. However, an additional 12,805
un- or misdiagnosed AS patients are predicted. The aggregate
annual costs of AS in Australia in 2004 are estimated to be
between AUS$109,432,035 and AUS$483,010,549, depending
on methods used to assess indirect costs. Direct Health Care
costs of AS are expected to be approximately A$34 million in
2004, accounting for 7%–31% of the total burden. CONCLU-
SIONS: Comparison of the aggregate costs of AS with other cost-
of-illness studies reported in Australia shows that the health care
costs of AS are lower than those for many other conditions.
However, the majority of the total costs of AS is attributable to
lost productivity highlighting the effect on a predominantly
working-age population. The burden of AS in Australia is
expected to increase in the next four years as population grows.
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OBJECTIVE: To evaluate the cost-effectiveness and the total cost
differences between valdecoxib 10 or 20mgqd and diclofenac 
75mg SR bid in the treatment of OA of the knee and/or hip.
METHODS: Study 063, a double-blind, randomized, 12-month
study, evaluated the efﬁcacy of valdecoxib 10mgqd (n = 259)
and valdecoxib 20mgqd (n = 261) versus diclofenac 75mg SR
bid (n = 262). Hospitalizations, unscheduled health care visits,
concomitant medications and unscheduled diagnostic and
medical procedures were prospectively collected during the trial.
This economic evaluation was conducted from a UK National
Health Service perspective, using published UK sources for cost.
Cost per averted ulcer was used as a cost-effectiveness measure.
RESULTS: Valdecoxib 10 and 20mgqd had comparable efﬁcacy
to diclofenac 75mg SR bid at all time points; none of the 95%
conﬁdence intervals (CIs) overlapped 15mm VAS, the smallest
difference determined to be clinically meaningful. The overall
incidence of adverse events was signiﬁcantly lower in both valde-
coxib groups than in the diclofenac group. Both valdecoxib
groups demonstrated a lower mean number of hospital days
(valdecoxib 10: 0.44 days; valdecoxib 20: 0.53 days; diclofenac:
1.02 days) and a smaller percentage of patients hospitalized
(valdecoxib 10: 7.3%; valdecoxib 20: 8.4%; diclofenac: 9.5%).
The valdecoxib 10mg group resulted in lower mean total costs
than the diclofenac group with a treatment cost difference of—
£129.20 (95% CI: -£448.80, £190.39). The corresponding dif-
ference between the valdecoxib 20mg group and the diclofenac
group was -£79.74 (95% CI: -£400.92, £241.44). Cost per
averted ulcer showed valdecoxib as the dominant therapy with
fewer ulcers and lower total medical costs. CONCLUSIONS:
Valdecoxib 10 and 20mgqd provided comparable efﬁcacy with
a more beneﬁcial safety proﬁle at a similar total medical cost
compared to diclofenac 75mg bid in treating OA.
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OBJECTIVE: To evaluate the determinants of costs and quality
of life for patients in Australia with the systemic rheumatic 
disorder ankylosing spondylitis (AS). METHODS: The study
employed a survey of 143 AS patients in Australia to collect
information about respondents’ disease history, quality of life,
health care resource utilisation and employment. Patient-level
estimation of total (direct and indirect) costs was performed.
Two disease status instruments measured disease activity and
level of disability: Bath Ankylosing Spondylitis Function Index
(BASFI) and Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). The burden of AS on quality of life was assessed using
utility values derived by the Assessment of Quality of Life
(AQoL) scale. RESULTS: The mean utility value across the sur-
veyed population was 0.56. Utilities ranged from 0.02 to 1.00,
with a median of 0.58 and a mode of 0.84. Mean BASFI and
BASDAI scores were 4.1 and 4.8, respectively. The mean cost per
patient over the 3 months prior to the survey was estimated to
be between AUS$2188 and AUS$6870 depending on the method
used to value indirect costs. Linear regression showed signiﬁcant
associations between utility values and BASFI and BASDAI
scores. Log-linear regression of Health Care and indirect costs
against respondents’ BASFI and BASDAI scores showed a sig-
niﬁcant association when each of these instruments is used to
predict health care costs. Log-linear regression of total costs also
showed that these increased with disease severity. CONCLU-
SIONS: BASFI and BASDAI scores compared with utility values
show an intuitive relationship: as disease severity decreases,
utility scores increase. Similarly, total costs are positively related
to disease severity. This study showed the costs and quality of
life effects of AS can be predicted by patients’ disease severity.
Knowledge of the predictors of costs enable policies and/or
health care interventions to be adopted that help to minimise
these costs.
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OBJECTIVES: We performed a macro-economic assessment of
the cost of osteoarthritis in 2002 and compared our results to
those computed in 1991 in an earlier study using the same
methodology. METHODS: The macro-economic cost assessment
was based on prevalence data. Medical consumption items were
described both in term of quantity and price. Data were collected
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from permanent surveys on medical prescription, from the
French cost per DRG database, and from various other data
sources. Perspective was that of health insurance and prices were
consequently based on reimbursement tariffs. RESULTS: From
1991 to 2002, the direct medical cost of osteoarthritis in France
has raised by 156% (from 0.64 to 1.64 billion Euros), i.e 9%
per year. The number of treated patients increased by 54% (from
3 million to 4.6 million), so that the cost per patient rose by
4.8% per year in average. Taking the GDP price index as deﬂa-
tor, the real average annual rates of growth per treated patient
were 3.3%, 0.3%, 7.4% and 3.7% respectively for total
expenses, doctors’ visits, pharmaceuticals and hospitalisations.
Sick leave cost to health insurance rose by 2.5% per year and
per patient in real terms. CONCLUSIONS: During the past
eleven years, the cost of osteoarthritis has substantially raised in
France. Half of the growth was attributable to the number of
treated patients and to general inﬂation, the other half being due
to changes in the treatment patterns, especially in pharmaceuti-
cal prescriptions. The emergence of new treatments such as
COX-2 inhibitors may largely explain this tendency. Hospital
costs also showed a marked growth, certainly due to the gener-
alisation of hip or knee arthroplasty surgery procedures. In the
future, it may be thought that the cost will continue to grow at
a similar rate under the inﬂuence of both demographic factors
and treatment innovations.
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OBJECTIVES: We report methodology and results of a post-
launch study which was commissioned by French Health
Authorities in order to measure the effectiveness and cost of
Suplasyn(r), a hyaluronic acid indicated in the treatment of knee
osteoarthritis, in real life conditions. METHODS: An observa-
tional, multicentric, prospective, longitudinal study was designed
in order to compare pain status, functional capacity, quality of
life and cost in patients with knee osteoarthritis, before and after
treatment with Suplasyn(r). Patients should meet the American
College of Rheumatology criteria for osteoarthritis and be cur-
rently treated by analgesics or nonsteroidal anti-inﬂammatory
drugs (NSAIDs). The decision to treat with Suplasyn(r) was left
to the investigators’ discretion. Treated patients were followed
retrospectively during three months and prospectively during six
months. Main evaluations were performed at initiation (V0) and
at three (V4) and six months (V5). Cost were compared over
three 3-month periods, P1 (before Suplasyn(r) injection), P2
(V0–V4) and P3 (V4–V5). They were computed in the perspec-
tive of public health insurance. RESULTS: In total, 296 patients
were included. Mean age was 68.67 ± 10.26 years. The main
clinical criterion, the WOMAC score, showed a signiﬁcant
improvement for both functional and pain subscales over the
time: scores at V4 and V5 were signiﬁcantly reduced compared
to V0 (p < 0.0001). The SF-12 Quality-of-Life scale was signif-
icantly improved for “physical” (p < 0.0001) and “mental” (p <
0.0001) dimensions. Between P1 and P3, the proportions of
patients receiving NSAIDs and Proton Pump Inhibitors fell
respectively from 68.6% to 29.1%, and from 19.3% to 8.7% (p
< 0.0001). Finally, the average medical cost per patient decreased
from 233.59 EUR (IC95%: 202.14–265.04) in P1 to 205.64
(IC95%: 191.70–219.57) in P2 and to 145.20 (IC95%:
77.36–213.05) in P3. CONCLUSIONS: In real life conditions,
Suplasyn(r) signiﬁcantly improves function, pain and quality-of-
life of patients with knee osteoarthritis and reduces medical
treatment cost.
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OBJECTIVE: The aim of this study was to compare the eco-
nomic consequences of the treatment of elderly patients with
selective COX-2 inhibitors (Celecoxib and Rofecoxib) and non-
selective NSAIDs. METHODS: A cost-effectiveness analysis
compared costs and effects of Celecoxib versus NSAIDs, versus
Diclofenac plus Misoprostol and versus Rofecoxib in the per-
spective of the Italian National Health Service (NHS). Effects
were derived from the study of Mamdani and colleagues (BNJ
2002; 325:624–627). Direct costs were measured (hospitalisa-
tion and pharmacological costs). Pharmacological costs were
quantiﬁed according to the Italian market price of the drugs.
Hospitalisation costs were quantiﬁed on the basis of DRG tariffs.
Effects were expressed as reduction in hospitalisation for upper
gastrointestinal haemorrhage. The mean duration of follow-up
was 12 months. A sensitivity analysis was conducted on unit cost
of drugs and hospitalisations. RESULTS: Clinical effects of treat-
ing an hypothetical cohort of 1000 patients for up to 12 months
with Celecoxib would correspond to an extra cost of 29.256,98€
and of 39.120,09€ per bleeding avoided compared to NSAIDs
and of 19.157,27€ and of 33.951,94€ per bleeding avoided com-
pared to Diclofenac/Misoprostol. The therapy with Celecoxib
dominates Rofecoxib as it is less costly and more effective. CON-
CLUSIONS: Treating subjects aged ≥66 years with Celecoxib is
more effective but also more costly than with NSAIDs and with
Diclofenac plus Misoprostol. On the contrary, treating elderly
subjects with Celecoxib is not only more effective but also less
costly than with Rofecoxib.
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OBJECTIVE: To evaluate the cost of treatment of FS in Italy and
its determinants. METHODS: Multicenter retrospective cost of
care study with patients enrolled from 28 Italian rheumatologic
centers. Time: 12 months. Cost: we quantiﬁed direct costs attrib-
utable to FS management: drugs, hospitalisations, physicians’
visits, diagnostic tests, and other medical services (e.g.
ionophoresis, mesotherapy, massage, thermal baths). Costs were
estimated applying the National Health Service (NHS) tariffs
expressed in Euro 2001. Perspective: NHS and patients perspec-
tive. RESULTS: We enrolled 402 patients with FS (mean age 48.4
± 12.3 years old), 94.8% women. The mean annual cost per
patient was euro 880.1 ± 1007.5: 33.7% attributable to hospi-
talisations, 17.45% to drugs and 17.7% to other pain coping
strategies. Anti-inﬂammatory drugs were the mainly used drugs
(72.1% of the patients used anti-inﬂammatory drugs). CON-
CLUSION: The cost of ﬁbromyalgia treatment was estimated for
the ﬁrst time in Italy. The mean yearly cost is 880€ and it is prin-
cipally caused by high use of symptomatic drugs and other pain
coping strategies.
